To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
- Conditions
- Migraine
- Interventions
- Registration Number
- NCT02542605
- Lead Sponsor
- Amgen
- Brief Summary
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
- Adults ≥ 18 to ≤ 45 years of age upon entry into screening
- History of migraine headaches without aura for ≥ 6 months prior to screening according to the International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
- Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior to screening
- History of migraine with aura, cluster headache or hemiplegic migraine headache according to the IHS Classification ICHD-II (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
- ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during screening period
- Other headache disorders (except for episodic tension-type headache <5 days/month)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PACAP-38 Challenge Agent PACAP-38 Challenge Agent In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B. Placebo Placebo Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks. Placebo PACAP-38 Challenge Agent Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks. Erenumab PACAP-38 Challenge Agent Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks. Erenumab Erenumab Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
- Primary Outcome Measures
Name Time Method Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion Part B randomization phase day 8 plus 24 hours. On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
A MLA was defined as fulfilling 1 of the 2 criteria:
1. Headache with at least 2 of the following characteristics: unilateral location, pulsating quality, moderate or severe pain intensity, aggravated by/causing avoidance of routine physical activity. Additionally, during the headache at least 1 of the following: nausea and/or vomiting, photophobia or phonophobia.
2. Headache described as mimicking usual migraine attack treated with triptan.
- Secondary Outcome Measures
Name Time Method Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS Part B randomization phase baseline and day 1, day 8 and EOS (week 12). Systolic and diastolic BP was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS Part B randomization phase baseline and day 1, day 8 and EOS (week 12). Respiratory rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Blood urea was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Creatine Kinase was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Direct bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d) Part B randomization phase baseline and 84 days post-dose. The mean AUC84d for erenumab for the Part B randomization phase is presented.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Part B randomization phase day 1 until EOS (up to 12 weeks). TEAEs were summarised for days 1 to 7 after the participants received placebo or erenumab infusion on day 1 of the Part B randomization phase. TEAEs were also summarized from day 8 to end of study (EOS) after participants had received both investigational product (placebo or erenumab) and the second dose of PACAP-38 on day 8.
Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion Part B randomization phase day 8 plus 24 hours. On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS Part B randomization phase baseline and day 8, day 9 and EOS (week 12). ALP, ALT and AST were assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Total bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS Part B randomization phase baseline and day 1, day 8 and EOS (week 12). Heart rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS Part B randomization phase baseline and day 1, day 8 and EOS (week 12). Temperature was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Creatinine was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Eosinophil count was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h) Part B randomization phase 1 hour post-dose day 1. The mean serum erenumab concentration at 1 hour post-dose on day 1 of Part B randomization phase is presented.
Number of Participants With Anti-Erenumab Antibodies Part B randomization phase baseline and EOS. Participants were tested for binding antibodies and neutralizing antibodies at baseline and following treatment with erenumab.
Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Blood glucose was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS Part B randomization baseline and day 8, day 9 and EOS (week 12). Hemoglobin A1C was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Part B randomization phase baseline and EOS. At baseline, 12-lead ECGs were performed in a standardized method, in triplicate, and approximately 30 seconds apart, prior to blood draws or other invasive procedures. Single ECGs were performed from Day 1 to EOS. ECG results were reviewed by the investigator and classified as: normal, abnormal not clinically significant or abnormal, clinically significant. The number of participants with abnormal, clinically significant changes in ECG results at EOS are presented.
Number of Participants With Clinically Significant Changes in Physical Parameters Part B randomization phase baseline and EOS. Physical examinations were performed by an investigator and any abnormal findings, judged to be clinically significant were recorded as an AE. The number of participants with clinically significant changes in physical parameters at EOS are presented.
Number of Participants With Clinically Significant Changes in Neurological Assessments Part B randomization phase baseline and EOS. Neurological examinations including assessment of cranial nerves, motor system, sensory system (including testing for pain sensation \[pin prick\], light touch sensation \[brush\], von Frey, and vibratory sense), reflexes, and cerebellar function were performed by the investigator and classified as normal or abnormal. Any abnormal findings, judged by the investigator to be clinically significant, were recorded as an AE. The number of participants with clinically significant changes in neurological assessments at EOS are presented.
Trial Locations
- Locations (1)
Research Site
🇳🇱Leiden, Netherlands